Aliskiren/amlodipine

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 451604217

| type = combo

| component1 = Aliskiren

| class1 = Renin inhibitor

| component2 = Amlodipine

| class2 = Calcium channel blocker (dihydropyridine)

| tradename = Tekamlo, Rasilamlo

| Drugs.com = {{drugs.com|ppa|aliskiren-and-amlodipine}}

| licence_EU =

| licence_US = Tekamlo

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category = C in first trimester;
D in second and third trimesters

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Rx

| dependency_liability =

| routes_of_administration = By mouth

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1416233-20-9

| ATC_prefix = C09

| ATC_suffix = XA53

| PubChem =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG =

}}

The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,{{cite journal | vauthors = Pfeiffer D, Rennie N, Papst CC, Zhang J | title = Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥ | journal = Current Vascular Pharmacology | volume = 10 | issue = 6 | pages = 773–80 | date = November 2012 | pmid = 22303911 | doi = 10.2174/157016112803520945 }} with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.{{cite journal | vauthors = Axthelm C, Sieder C, Meister F, Kaiser E | title = Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg | journal = Current Medical Research and Opinion | volume = 28 | issue = 1 | pages = 69–78 | date = January 2012 | pmid = 22117838 | doi = 10.1185/03007995.2011.637914 | s2cid = 25693979 }}